Genmab - Video: Daratumumab and high-risk cytogenetics
84788 Helge Larsen/PI-redaktør 22/6 2020 11:30
"During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: Can daratumumab (dara) overcome the negative prognostic impact of high-risk cytogenetics?
Dara has impacted the lives of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory disease. However, the clinical activity of dara is yet to be determined in patients with NDMM and high-risk cytogenetics.
At this year's virtual EHA Annual Congress, results will be presented from a meta analysis of patients with high-risk cytogenetics treated in trials evaluating an MM backbone treatment ± dara. Here, Luciano Costa highlights the benefit of dara observed in this setting and other key results".
Dara has impacted the lives of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory disease. However, the clinical activity of dara is yet to be determined in patients with NDMM and high-risk cytogenetics.
At this year's virtual EHA Annual Congress, results will be presented from a meta analysis of patients with high-risk cytogenetics treated in trials evaluating an MM backbone treatment ± dara. Here, Luciano Costa highlights the benefit of dara observed in this setting and other key results".
